Effects of Felodipine ER, a Dihydropyridine Calcium Antagonist, on Blood Pressure and Serum Lipids

• Published in: Current medical research and opinion Vol. 14; no. 2; pp. 97 - 103
• Main Authors: Reuter, M. K., Lorenz, H., Verho, P., Smith, N., Degen, A., Verho, M.
• Format: Journal Article
• Language: English
• Published: Reading Informa UK Ltd 1998; Taylor & Francis; Librapharm; Informa Healthcare
• Subjects: Adult; Aged; Antihypertensive agents; Antihypertensive Agents - pharmacology; Antihypertensive Agents - therapeutic use; Antihypertensive efficacy; Biological and medical sciences; Blood Pressure - drug effects; Calcium Channel Blockers - pharmacology; Calcium Channel Blockers - therapeutic use; Cardiovascular system; Felodipine; Felodipine - pharmacology; Felodipine - therapeutic use; Female; Humans; Hyperlipidemias - drug therapy; Hypertension - drug therapy; Hypolipidemic Agents - pharmacology; Hypolipidemic Agents - therapeutic use; Lipids; Lipids - blood; Lipoproteins; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Human; Hypertension; Controlled release form; Calcium antagonist; Oral administration; Cardiovascular disease; Chemotherapy; Lipemia; Treatment; Antihypertensive agent; Dihydropyridine derivatives; Hyperlipemia; Felodipine
• ISSN: 0300-7995; 1473-4877
• DOI: 10.1185/03007999809113348

Summary In an open trial, the antihypertensive efficacy of felodipine and its efects on lipid metabolism were investigated in 117 Nordic patients with mild to moderate essential hypertension and hyperlipidaemia. In the intent-to-treat analysis (n = 106) a significant (p<0.01) drop in the mean systolic and diastolic blood pressure values was observed between baseline and 24 weeks' treatment from 1571100 mmHg to 145192 (supine) and from 1551103 to 145/96 mmHg (erect). No relevant differences were seen in the pulse rate. Median total cholesterol and triglycerides remained unchanged, whereas HDL-cholesterol increased significantly from 1.30mmolll to 1.33mmol/l (p<0.02); LDL- and VLDL-cholesterol, apolipoprotein A1 and apolipoprotein B remained unchanged during the 24-week treatment period. In the per protocol analysis (n = 76), blood pressure values changed significantly from 1581100 mmHg to 144191 mmHg (supine) and from 1571104 mmHg to 143195 mmHg (erect) (p<0.01 for both). HDL-cholesterol increased significantly (p = 0.03), whereas LDL- and VLDL-cholesterol, total cholesterol and triglycerides, as well as the apolipoproteins, remained unchanged during the trial. Felodipine thus proved to possess positive effects on lipid parameters in hypertensive patients.